Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australia Aims To Drive Etanercept Uptake By Broadening Brenzys Listing

Executive Summary

Australian authorities are looking to drive uptake of biosimilar etanercept by broadening a reimbursement listing for MSD’s Brenzys, while an advisory committee continues to ponder listings for trastuzumab biosimilars.

You may also be interested in...

Australia Lists Celltrion’s Truxima For Cancer

Celltrion Healthcare’s Truxima has become the second rituximab biosimilar to be listed on Australia’s Pharmaceutical Benefits Schedule. But unlike Sandoz’ Riximyo version, Truxima is only eligible for oncology indications under a chemotherapy funding scheme.

Juno And Celltrion Partner For Australian Biosimilars Push

Australia’s Juno Pharmaceuticals has struck a deal with Korea’s Celltrion to partner on marketing biosimilar trastuzumab and rituximab.

Australian Advisors Will Ponder Sandoz’ Pegfilgrastim And Pfizer’s Trastuzumab

A body that advises Australia’s Department of Health on reimbursement will in November consider listing applications for Sandoz’ Ziextenzo pegfilgrastim candidate and well as for Pfizer’s recently authorized Trazimera trastuzumab brand.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts